Propanc Biopharma Stock EBITDA
Propanc Biopharma fundamentals help investors to digest information that contributes to Propanc Biopharma's financial success or failures. It also enables traders to predict the movement of Propanc Pink Sheet. The fundamental analysis module provides a way to measure Propanc Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Propanc Biopharma pink sheet.
Propanc |
Propanc Biopharma Company EBITDA Analysis
Propanc Biopharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Propanc Biopharma EBITDA | (2.97 M) |
Most of Propanc Biopharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Propanc Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Propanc Biopharma reported earnings before interest,tax, depreciation and amortization of (2.97 Million). This is 100.34% lower than that of the Healthcare sector and 102.97% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 100.08% higher than that of the company.
Propanc EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Propanc Biopharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Propanc Biopharma could also be used in its relative valuation, which is a method of valuing Propanc Biopharma by comparing valuation metrics of similar companies.Propanc Biopharma is currently under evaluation in ebitda category among its peers.
Propanc Fundamentals
| Current Valuation | 1.32 M | |||
| Shares Outstanding | 691.17 K | |||
| Shares Owned By Insiders | 1.94 % | |||
| Shares Owned By Institutions | 1.94 % | |||
| EBITDA | (2.97 M) | |||
| Net Income | (3.67 M) | |||
| Cash And Equivalents | 51.22 K | |||
| Cash Per Share | 0.07 X | |||
| Total Debt | 1.1 M | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | (4.44) X | |||
| Cash Flow From Operations | (1.3 M) | |||
| Earnings Per Share | (16.63) X | |||
| Beta | 2.05 | |||
| Market Capitalization | 259.19 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Propanc Pink Sheet
If you are still planning to invest in Propanc Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Propanc Biopharma's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |